⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059268 | 0.79 | — | — | |
| SCHEMBL12656248 | 0.64 | — | — | |
| SCHEMBL12113 | 0.63 | — | — | |
| SCHEMBL3221 | 0.61 | — | — | |
| SCHEMBL600787 | 0.61 | — | — | |
| SCHEMBL1810674 | 0.61 | — | — | |
| SCHEMBL2697111 | 0.61 | — | — | |
| SCHEMBL6600564 | 0.61 | — | — | |
| SCHEMBL2278018 | 0.61 | — | — | |
| SCHEMBL5359 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185468-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2019-06-20 | — | — | US | claimed |
| US-10189834-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-01-29 | — | — | US | claimed |
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | claimed |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | claimed |
| US-20180134699-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-05-17 | — | — | US | claimed |
| EP-3140303-B1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | claimed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | claimed |
| US-9771354-B2 | Pyrazole p38 map kinase inhibitors | RESPIVERT LTD. (GB) | 2017-09-26 | — | — | US | claimed |
| EP-3140303-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2017-03-15 | — | — | EP | claimed |
| EP-2680844-B1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-10-19 | — | — | EP | claimed |
| EP-2358697-A1 | Isoindoline compounds for use in the treatment of cancer | CELGENE CORPORATION (US) | 2011-08-24 | — | — | EP | claimed |
| WO-2010053732-A1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORPORATION (US) | 2010-05-14 | — | — | WO | claimed |
| EP-2124560-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008100565-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | claimed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | claimed |
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | claimed |
| EP-1505063-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-02-09 | — | — | EP | claimed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | claimed |
| US-20030236267-A1 | Benzimidazole derivatives | MSD K.K. (JP) | 2003-12-25 | — | — | US | claimed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | claimed |